236. 偽性副甲状腺機能低下症 ［臨床試験数：4，薬物数：3（DrugBank：2），標的遺伝子数：20，標的パスウェイ数：28］
Searched query = "Pseudohypoparathyroidism"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03718403 | April 10, 2019 | 5 November 2018 | Effect of Theophylline in Pseudohypoparathyroidism | Effect of Theophylline in Pseudohypoparathyroidism | PHP Ia;PHP IB;Php1C | Drug: Theophylline | Massachusetts General Hospital | Not recruiting | 5 Years | 21 Years | All | 40 | Phase 4 | ||
| 2 | NCT03029429 | September 1, 2018 | 15 July 2019 | Theophylline Treatment for Pseudohypoparathyroidism | Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism | Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy | Drug: Theophylline;Drug: Placebos | Vanderbilt University Medical Center | Harvard University | Recruiting | 2 Years | 25 Years | All | 34 | Phase 2 | United States |
| 3 | NCT02463409 | June 2015 | 16 December 2017 | Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy) | Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a | Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy | Drug: Theophylline | Vanderbilt University Medical Center | Massachusetts General Hospital | Not recruiting | 10 Years | 21 Years | All | 6 | Phase 2 | United States |
| 4 | NCT00497484 | February 1995 | 19 February 2015 | Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia) | Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia) | Pseudohypoparathyroidism;Growth Hormone Deficiency, Dwarfism | Drug: recombinant human somatotropin | University of Milan | Eli Lilly and Company | Not recruiting | 1 Year | 18 Years | Both | N/A | Italy |